Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52
- 296 Downloads
The tumor protein D52 (TPD52) is an oncogene overexpressed in breast cancer. Although the oncogenic effects of TPD52 are well recognized, how its expression and the role in migration/invasion is still not clear. This study tried to explore the regulative role of microRNA-34a (miR-34a), a tumor suppressive miRNA, on TPD52 expression in breast cancer. The expression of miR-34a was found significantly decreased in breast cancer specimens with lymph node metastases and breast cancer cell lines. The clinicopathological characteristics analyzed showed that lower expression levels of miR-34a were associated with advanced clinical stages. Moreover, TPD52 was demonstrated as one of miR-34a direct targets in human breast cancer cells. miR-34a was further found significantly repress epithelial-mesenchymal transition (EMT) and inhibit breast cancer cell migration and invasion via TPD52. These findings indicate that miR-34a inhibits breast cancer progression and metastasis through targeting TPD52. Consequently, our data strongly suggested that oncogenic TPD52 pathway regulated by miR-34a might be useful to reveal new therapeutic targets for breast cancer.
KeywordsHuman breast cancer miR-34a TPD52 Epithelial-mesenchymal transition
Dulbelcco’s modified Eagle’s media
Fetal bovine serum
Institutional Review Board
Quantitative real-time reverse transcription-PCR
Transforming growth factor-beta
Tumor protein D52
This study was supported by the Foundation of Educational Committee of Heilongjiang Province of China (Grant No. 12541311).
Compliance with ethical standards
The authors declare that all the patients, involved in this study, signed informed consent forms according to our institutional guidelines, and the study was approved by Institutional Review Board (IRB) protocols of Harbin Medical University. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Conflicts of interest
- 1.Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015.Google Scholar
- 2.Hart CD, Migliaccio I, Malorni L, Guarducci C, Biganzoli L, Leo AD. Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. Nat Rev Clin Oncol. 2015.Google Scholar
- 12.Goh JN, Loo SY, Datta A, Siveen KS, Yap WN, Cai W, Shin EM, Wang C, Kim JE, Chan M, Dharmarajan AM, Lee AS, Lobie PE, Yap CT, Kumar AP. MicroRNAs in breast cancer: regulatory roles governing the hallmarks of cancer. Biol Rev Camb Philos Soc. 2015.Google Scholar
- 14.Agarwal S, Hanna J. Quantitative assessment of miR34a as an independent prognostic marker in breast cancer. 2015;112:61–68.Google Scholar
- 34.Kaller M, Liffers ST, Oeljeklaus S, Kuhlmann K, Roh S, Hoffmann R, Warscheid B, Hermeking H: Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics 2011;10:M111 010462.Google Scholar
- 36.Roslan N, Bièche I, Bright RK, Lidereau R, Chen Y, Byrne JA. TPD52 represents a survival factor in ERBB2-amplified breast cancer cells. Mol Carcinog. 2014;53:807–19.Google Scholar
- 39.Katoh K, Nakanishi Y, Akimoto S, Yoshimura K, Takagi M, Sakamoto M, et al. Correlation between laminin-5 gamma2 chain expression and epidermal growth factor receptor expression and its clinicopathological significance in squamous cell carcinoma of the tongue. Oncology. 2002;62:318–26.CrossRefPubMedGoogle Scholar